PTPA and neoplasm: Several small molecule activators of PP2A (SMAP), which emerged from a medicinal chemistry campaign to re-engineer tricyclic neuroleptics [17], have been shown to decrease tumor growth in models of lung [15], prostate [18], pancreatic [19], and breast [20] cancers and glioblastoma [21,22].